Reviewing the inter partes review

The establishment of the US Patent Trial and Appeal Board (PTAB) in 2012 changed the game for patent owners. And while life science patents have not always been under the spotlight, recent trends suggest more such patents are being reviewed than ever before.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pfizer’s US Paxlovid patent fight turns on a single error

25 June 2026 The Federal Circuit has brought Paxloid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.

Biotechnology

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

25 June 2026 Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines.

Europe

Novo secures website blocking to tackle fake weight-loss drugs

25 June 2026 A UK judge extends a blocking order aimed at ISPs including BT, EE, and Sky, allowing the maker of Ozempic and Wegovy to add infringing sites that sell counterfeits without returning to court.

More features

Pfizer’s US Paxlovid patent fight turns on a single error

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

Novo secures website blocking to tackle fake weight-loss drugs

GLP-1 patents and Africa: The COVID-19 lessons we still have not learned

Cooley Asia transactions duo make rival firm move

Insilico lands potential $2.5bn AI biotech partnership

‘Blatant imitation’: Indian court blocks copycat pharma branding

UPC hands Occlutech second win against Chinese medtech company in a month

Reviewing the inter partes review

More on this story

Editor's picks

Editor's picks

More features